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Hepatitis B Virus: A Comprehensive Strategy 
for Eliminating Transmission in the 
United States Through Universal 
Childhood Vaccination
Recommendations of the Im m unization Practices 
Advisory Com m ittee (ACIP)
The following statement updates all previous recommendations on protec­
tion against hepatitis B virus infection, including use o f hepatitis B vaccine and 
hepatitis B immune globulin for prophylaxis against hepatitis B virus infection 
(MMWR 1985:34:313-24,329-35, MMWR 1987;36:353-66, and MMWR 1990,39 
[No.RR-2]:8-19) and universal screening o f pregnant women to prevent peri­
natal hepatitis B virus transmission (MMWR 1988,37:341-46,51, and MMWR 
1990;39[No.RR-2]:8-19). Recommendations concerning the prevention of other 
types o f viral hepatitis are found in MMWR 1990;39(No.RR-2):1-8, 22-26.
This document provides the rationale for a comprehensive strategy to 
eliminate transmission of hepatitis B virus in the United States. This prevention 
strategy includes making hepatitis B vaccine a part o f routine vaccination 
schedules for all infants.
INTRODUCTION
The acute and chronic consequences of hepatitis B virus (HBV) infection are major 
health problems in the United States. The reported incidence of acute hepatitis B 
increased by 37% from 1979 to 1989, and an estimated 200,000-300,000 new 
infections occurred annually during the period 1980-1991. The estimated 1 million- 
1.25 million persons with chronic HBV infection in the United States are potentially 
infectious to others. In addition, many chronically infected persons are at risk of 
long-term sequelae, such as chronic liver disease and primary hepatocellular 
carcinoma; each year approximately 4,000-5,000 of these persons die from chronic 
liver disease (7).
Immunization with hepatitis B vaccine is the most effective means of preventing 
HBV infection and its consequences. In the United States, most infections occur 
among adults and adolescents (2,3). The recommended strategy for preventing these 
infections has been the selective vaccination of persons with identified risk factors 
(1,2). However, this strategy has not lowered the incidence of hepatitis B, primarily 
because vaccinating persons engaged in high-risk behaviors, life-styles, or occupa­
tions before they become infected generally has not been feasible. In addition, many 
infected persons have no identifiable source for their infections and thus cannot be 
targeted for vaccination (2).
Preventing HBV transmission during early childhood is important because of the 
high likelihood of chronic HBV infection and chronic liver disease that occurs when 
children less than 5 years of age become infected (3). Testing to identify pregnant
i
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women who are hepatitis B surface antigen(HBsAg)-positive and providing their 
infants with immunoprophylaxis effectively prevents HBV transmission during the 
perinatal period (4,5). Integrating hepatitis B vaccine into childhood vaccination 
schedules in populations with high rates of childhood infection (e.g., Alaskan Natives 
and Pacific Islanders) has been shown to interrupt HBV transmission (5).
This document provides the rationale for a comprehensive strategy to eliminate 
transmission of HBV and ultimately reduce the incidence of hepatitis B and hepatitis 
B-associated chronic liver disease in the United States. The recommendations for 
implementing this strategy include making hepatitis B vaccine a part of routine 
vaccination schedules for infants.
EPIDEMIOLOGY AND PREVENTION OF HEPATITIS B VIRUS 
INFECTION
Infections among Infants and Children
In the United States, children become infected with HBV through a variety of 
means. The risk of perinatal HBV infection among infants born to HBV-infected 
mothers ranges from 10% to 85%, depending on each mother's hepatitis B e antigen 
(HBeAg) status (3,7,8). Infants who become infected by perinatal transmission have 
a 90% risk of chronic infection, and up to 25% will die of chronic liver disease as adults 
(9). Even when not infected during the perinatal period, children of HBV-infected 
mothers remain at high risk of acquiring chronic HBV infection by person-to-person 
(horizontal) transmission during the first 5 years of life (10). More than 90% of these 
infections can be prevented if HBsAg-positive mothers are identified so that their 
infants can receive hepatitis B vaccine and hepatitis B immune globulin (HBIG) soon 
after birth (4,5).
Because screening selected pregnant women for HBsAg has failed to identify a 
high proportion of HBV-infected mothers (11,12), prenatal HBsAg testing of all 
pregnant women is now recommended (1,13,14). Universal prenatal testing would 
identify an estimated 22,000 HBsAg-positive women and could prevent at least 6,000 
chronic HBV infections annually (3). Screening and vaccination programs for women 
and infants receiving care in the public sector have already been initiated through 
state immunization projects.
Horizontal transmission of HBV during the first 5 years of life occurs frequently in 
populations in which HBV infection is endemic. The risk of chronic infection is age 
dependent, ranging from 30% to 60% for children 1-5 years of age (75). Worldwide, 
it has been recommended that, in populations in which HBV infection is acquired 
during childhood, hepatitis B vaccine should be integrated into routine vaccination 
schedules for infants, usually as a part of the World Health Organization's Expanded 
Programme on Immunization (76). In the United States, racial/ethnic groups shown 
to have high rates of childhood HBV infection include Alaskan Natives (6,17), Pacific 
Islanders (76), and infants of first-generation immigrant mothers from parts of the 
world where HBV infection is endemic, especially Asia ( 19,20). Vaccination programs 
to prevent perinatal, childhood, and adult HBV infections among Alaskan Natives 
were begun in late 1982; as a result, the incidence of acute hepatitis B in this 
population has declined by over 99% (6). Hepatitis B vaccine was integrated into
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vaccination schedules for infants in American Samoa beginning in 1986 and by 1990 
was incorporated into the schedules of the remaining Pacific Islands under U.S. 
jurisdiction.
Each year, approximately 150,000 infants are born to women who have immi­
grated to the United States from areas of the world where HBV infection is highly 
endemic (3). Children born to HBsAg-positive mothers can be identified through 
prenatal screening programs. However, children born to HBsAg-negative immigrant 
mothers are still at high risk of acquiring HBV infection, usually from other HBV 
carriers in their families or communities (3,19,20). Infections among these children 
can be prevented by making hepatitis B vaccine part of their routine infant vaccina­
tions (7).
Infections among Adolescents and Adults
In the United States most persons with hepatitis B acquire the infection as 
adolescents or adults. Several specific modes of transmission have been identified, 
including sexual contact, especially among homosexual men and persons with 
multiple heterosexual partners; parenteral drug use; occupational exposures; house­
hold contact with a person who has an acute infection or with a chronic carrier; 
receipt of certain blood products; and hemodialysis. However, over one-third of 
patients with acute hepatitis B do not have readily identifiable risk factors (1,2).
The rates of HBV infection differ significantly among various racial and ethnic 
groups (2,21). For example, the prevalence of infection among adolescents and 
adults has been shown to be threefold to fourfold greater for blacks than for whites 
and to be associated with serologic evidence of previous infection with syphilis 
( 21, 2 2 ) .
Efforts to vaccinate persons in the major risk groups have had limited success. For 
example, programs directed at injecting drug users failed to motivate them to receive 
three doses of vaccine (CDC, unpublished data). Health-care providers are often not 
aware of groups at high risk of HBV infection and frequently do not identify 
candidates for vaccination during routine health-care visits (CDC, unpublished data). 
In addition, there has been limited vaccination of susceptible household and sexual 
contacts of HBsAg carriers identified in screening programs for blood donors (23). 
Hepatitis B vaccination of health-care workers appears to have resulted in a substan­
tial decrease in the rate of disease in this group, but has had little effect on overall 
rates of hepatitis B (2). Moreover, to achieve widespread vaccination of persons at 
occupational risk, regulations have had to be developed to ensure implementation of 
vaccination programs (24).
Educational programs to reduce parenteral drug use and unprotected sexual 
activity are important components of the strategy to prevent infection with the human 
immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome. 
These programs appear to have reduced the risk of HBV infections among homosex­
ual men but have not had an impact on hepatitis B attributable to parenteral drug use 
or heterosexual transmission (2). Educational efforts alone are not likely to fully 
eliminate the high-risk behaviors responsible for HBV transmission.
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EPIDEMIOLOGY AND PREVENTION OF HEPATITIS DELTA 
VIRUS INFECTION
Hepatitis delta virus (HDV) is a defective virus that causes infection only in the 
presence of active HBV infection (25). HDV infection occurs as either coinfection with 
HBV or superinfection of an HBV carrier. Coinfection usually resolves; superinfection, 
however, frequently causes chronic HDV infection and chronic active hepatitis. Both 
types of infection may cause fulminant hepatitis.
Routes of transmission are similar to those of HBV. In the United States, HDV 
infection most commonly affects persons at high risk of HBV infection, particularly 
injecting drug users and persons receiving clotting factor concentrates (26 ). Prevent­
ing acute and chronic HBV infection of susceptible persons will also prevent HDV 
infection.
STRATEGY TO ELIMINATE HEPATITIS B VIRUS TRANSMISSION
A comprehensive strategy to prevent HBV infection, acute hepatitis B, and the 
sequelae of HBV infection in the United States must eliminate transmission that 
occurs during infancy and childhood, as well as during adolescence and adulthood. In 
the United States it has become evident that HBV transmission cannot be prevented 
through vaccinating only the groups at high risk of infection. No current medical 
treatment will reliably eliminate chronic HBV infection and thus eliminate the source 
of new infections in susceptible persons (27). Therefore, new infections can be 
prevented only by immunizing susceptible persons with hepatitis B vaccine. Routine 
visits for prenatal and well-child care can be used to target hepatitis B prevention. A 
comprehensive prevention strategy includes a) prenatal testing of pregnant women 
for HBsAg to identify newborns who require immunoprophylaxis for the prevention 
of perinatal infection and to identify household contacts who should be vaccinated, b) 
routine vaccination of children born to HBsAg-negative mothers, c) vaccination of 
certain adolescents, and d) vaccination of adults at high risk of infection.
Infants and children can receive hepatitis B vaccine during routine health-care 
visits; no additional visits would be required. Costs include that of the vaccine and the 
incremental expense associated with delivering an additional vaccine during a 
scheduled health-care visit. Implementation of this immunization strategy would be 
greatly facilitated by the development and use of multiple-antigen vaccines (e.g., 
diphtheria-tetanus-pertussis[DTP]/hepatitis B, Haemophilus influenzae type b con- 
jugate/hepatitis B). These vaccines would reduce the number of injections received by 
the infant, reduce the cost of administration, and greatly facilitate widespread vaccine 
delivery.
Since most HBV infections occur among adults, disease control could be acceler­
ated by vaccinating emerging at-risk populations, such as adolescents and suscepti­
ble contacts of chronic HBV carriers. The recommendation for universal infant 
vaccination neither precludes vaccinating adults identified to be at high risk of 
infection nor alters previous recommendations for postexposure prophylaxis for 
hepatitis B (7).
The reduction in acute hepatitis B and hepatitis B-associated chronic liver disease 
resulting from universal infant vaccination may not become apparent for a number of 
years. However, universal HBsAg screening of pregnant women to prevent perinatal
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HBV infection has been shown to be cost saving (28, CDC, unpublished data), and the 
estimated cost of universal hepatitis B vaccination for infants is less than the direct 
medical and work-loss costs associated with the estimated 5% lifetime risk of 
infection (CDC, unpublished data). Currently, the cost of an infant's dose of hepatitis 
B vaccine delivered in the public sector is about the same as each of the other 
childhood vaccinations. Vaccinating adolescents and adults is substantially more 
expensive because of the higher vaccine cost and the higher implementation costs of 
delivering vaccine to target populations. In the long term, universal infant vaccination 
would eliminate the need for vaccinating adolescents and high-risk adults.
PROPHYLAXIS AGAINST HEPATITIS B VIRUS INFECTION
Two types of products are available for prophylaxis against HBV infection. 
Hepatitis B vaccine, which provides long-term protection against HBV infection, is 
recommended for both preexposure and postexposure prophylaxis. HBIG provides 
temporary protection (i.e., 3-6 months) and is indicated only in certain postexposure 
settings.
Hepatitis B Immune Globulin
HBIG is prepared from plasma known to contain a high titer of antibody against 
HBsAg (anti-HBs). In the United States, HBIG has an anti-HBs titer of >100,000 by 
radioimmunoassay. The human plasma from which HBIG is prepared is screened for 
antibodies to HIV; in addition, the process used to prepare HBIG inactivates and 
eliminates HIV from the final product. There is no evidence that HIV can be 
transmitted by HBIG (29,30).
Hepatitis B Vaccine
Two types of hepatitis B vaccine have been licensed in the United States. One, 
which was manufactured from the plasma of chronically infected persons, is no 
longer produced in the United States. The currently available vaccines are produced 
by recombinant DNA technology.
The recombinant vaccines are produced by using HBsAg synthesized by Saccha- 
romyces cerevisiae (common bakers' yeast), into which a plasmid containing the 
gene for HBsAg has been inserted. Purified HBsAg is obtained by lysing the yeast 
cells and separating HBsAg from the yeast components by biochemical and biophys­
ical techniques. Hepatitis B vaccines are packaged to contain 10-40 jig of HBsAg 
protein/mL after adsorption to aluminum hydroxide (0.5 mg/mL); thimerosal (1: 
20,000 concentration) is added as a preservative.
Routes and sites of administration.
The recommended series of three intramuscular doses of hepatitis B vaccine 
induces a protective antibody response (anti-HBs ^10 milli-international units [mlU]/ 
mL) in >90% of healthy adults and in >95% of infants, children, and adolescents 
(31-33). Hepatitis B vaccine should be administered only in the deltoid muscle of 
adults and children or in the anterolateral thigh muscle of neonates and infants; the 
immunogenicity of the vaccine for adults is substantially lower when injections are
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administered in the buttock (34). When hepatitis B vaccine is administered to infants 
at the same time as other vaccines, separate sites in the anterolateral thigh may be 
used for the multiple injections. This method is preferable to administering vaccine at 
sites such as the buttock or deltoid.
Compared with three standard doses admistered intramuscularly, three low doses 
of plasma-derived or recombinant vaccine administered intradermally to adults result 
in lower seroconversion rates (55%-81%) and lower final titers of anti-HBs (35-38), 
although four doses of plasma-derived vaccine administered intradermally have 
produced responses comparable with vaccine administered intramuscularly (39). 
Plasma-derived vaccine administered intradermally to infants and children does not 
induce an adequate antibody response (40). At this time, low-dose intradermal 
vaccination of adults should be performed only under research protocol with written 
informed consent. Persons who have been vaccinated intradermally should be tested 
for anti-HBs. Those with an inadequate response (anti-HBs <10 mlU/mL) should be 
revaccinated with three full doses of vaccine administered intramuscularly. Intrader­
mal vaccination should not be used for infants or children.
Vaccination during pregnancy.
On the basis of limited experience, there is no apparent risk of adverse effects to 
developing fetuses when hepatitis B vaccine is administered to pregnant women 
(CDC, unpublished data). The vaccine contains noninfectious HBsAg particles and 
should cause no risk to the fetus. HBV infection affecting a pregnant woman may 
result in severe disease for the mother and chronic infection for the newborn. 




Vaccination schedule and dose. The vaccination schedule most often used for 
adults and children has been three intramuscular injections, the second and third 
administered 1 and 6 months, respectively, after the first. An alternate schedule of 
four doses has been approved for one vaccine that would allow more rapid induction 
of immunity. However, for preexposure prophylaxis, there is no clear evidence that 
this regimen provides greater protection than that obtained with the standard 
three-dose schedule.
Each vaccine has been evaluated to determine the age-specific dose at which an 
optimum antibody response is achieved. The recommended dose varies by product 
and the recipient's age and, for infants, by the mother's HBsAg serologic status (Table 
1). In general, the vaccine dose for children and adolescents is 50%-75% lower than 
that required for adults (Table 1).
Incorporating hepatitis B vaccine into childhood vaccination schedules may 
require modifications of previously recommended schedules. However, a protective 
level of anti-HBs (^10 mlU/mL) was achieved when hepatitis B vaccine was 
administered in a variety of schedules, including those in which vaccination was 
begun soon after birth (5,8,41).
In a three-dose schedule, increasing the interval between the first and second 
doses of hepatitis B vaccine has little effect on immunogenicity or final antibody titer.
i
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The third dose confers optimal protection, acting as a booster dose. Longer intervals 
between the last two doses (4-12 months) result in higher final titers of anti-HBs 
(42,43). Several studies have shown that the currently licensed vaccines produce 
high rates of seroconversion (>95%) and induce adequate levels of anti-HBs when 
administered to infants at birth, 2 months, and 6 months of age or at 2 months, 4 
months, and 6 months of age (CDC, Merck Sharpe & Dohme, SmithKIine Beecham, 
unpublished data). When the vaccine is administered in four doses at 0, 1, 2, and 12 
months, the last dose is necessary to ensure the highest final antibody titer.
When hepatitis B vaccine has been administered at the same time as other 
vaccines, no interference with the antibody response of the other vaccines has been 
demonstrated (44).
If the vaccination series is interrupted after the first dose, the second dose should 
be administered as soon as possible. The second and third doses should be separated 
by an interval of at least 2 months. If only the third dose is delayed, it should be 
administered when convenient.
The immune response when one or two doses of a vaccine produced by one 
manufacturer are followed by subsequent doses from a different manufacturer has 
been shown to be comparable with that resulting from a full course of vaccination 
with a single vaccine.
Larger vaccine doses or an increased number of doses are required to induce 
protective antibody in a high proportion of hemodialysis patients (45,46) and may 
also be necessary for other immunocompromised persons (e.g., those who take 
immunosuppressive drugs or who are HIV positive), although few data are available 
concerning response to higher doses of vaccine by these patients (47).
Prevaccination testing for susceptibility. Susceptibility testing is not indicated for 
immunization programs for children or for most adolescents because of the low rate 
of HBV infection and the relatively low cost of vaccine. For adults, the decision to do
TABLE 1. Recommended doses of currently licensed hepatitis B vaccines
Recombivax HB* Engerix-B*
Group Dose (ixg) (mL) Dose (p.g) (mL)
Infants of HBsAgf-negative 
mothers and children 
<11 years 2.5 (0.25) 10 (0.5)
Infants of HBsAg-positive 
mothers; prevention of 
perinatal infection
5 (0.5) 10 (0.5)
Children and adolescents 
11-19 years 5 (0.5) 20 (1.0)
Adults >20 years 10 (1.0) 20 (1.0)
Dialysis patients and
other immunocompromised
persons 40 (1.0)* 40 (2.0)1
*Both vaccines are routinely administered in a three-dose series. Engerix-B has also been 
licensed for a four-dose series administered at 0, 1, 2, and 12 months. 
fHBsAg = Hepatitis B surface antigen.
5Special formulation.
^Two 1.0-mL doses administered at one site, in a four-dose schedule at 0, 1, 2, and 6 months.
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prevaccination testing should include an analysis of cost effectiveness because of the 
higher cost of the vaccine. Testing for prior infection should be considered for adults 
in risk groups with high rates of HBV infection (e.g., injecting drug users, homosexual 
men, and household contacts of HBV carriers). The decision for testing should be 
based on whether the costs of testing balance the costs of vaccine saved by not 
vaccinating already-infected persons. Estimates of the cost effectiveness of testing 
depend on three variables: the cost of vaccination, the cost of testing for suscepti­
bility, and the expected prevalence of immune persons. If susceptibility testing is 
being considered, careful attention should also be given to the likelihood of patient 
follow-up and vaccine delivery.
For routine testing, only one antibody test is necessary (antibody either to the core 
antigen [anti-HBc] or anti-HBs). Anti-HBc testing identifies all previously infected 
persons, including HBV carriers, but does not differentiate carriers and non-carriers. 
The presence of anti-HBs identifies previously infected persons, except for HBV 
carriers. Neither test has a particular advantage for groups expected to have HBV 
carrier rates <2%, such as health-care workers. Anti-HBc may be preferable so that 
unnecessary vaccination of HBV carriers can be avoided in groups with high carrier 
rates.
Postvaccination testing for serologic response. Such testing is not necessary 
after routine vaccination of infants, children, or adolescents. Testing for immunity is 
advised only for persons whose subsequent clinical management depends on 
knowledge of their immune status (e.g., infants born to HBsAg-positive mothers, 
dialysis patients and staff, and persons with HIV infection). Postvaccination testing 
should also be considered for persons at occupational risk who may have exposures 
from injuries with sharp instruments, because knowledge of their antibody response 
will aid in determining appropriate postexposure prophylaxis. When necessary, 
postvaccination testing should be performed from 1 to 6 months after completion of 
the vaccine series. Testing after immunoprophylaxis of infants born to HBsAg- 
positive mothers should be performed from 3 to 9 months after the completion of the 
vaccination series (see section on Postexposure prophylaxis).
Revaccination of nonresponders. When persons who do not respond to the 
primary vaccine series are revaccinated, 15%-25% produce an adequate antibody 
response after one additional dose and 30%-50% after three additional doses (48). 
Therefore, revaccination with one or more additional doses should be considered for 
persons who do not respond to vaccination initially.
Postexposure prophylaxis
After a person has been exposed to HBV, appropriate immunoprophylactic 
treatment can effectively prevent infection. The mainstay of postexposure immuno­
prophylaxis is hepatitis B vaccine, but in some settings the addition of HBIG will 
provide some increase in protection. Table 2 provides a guide to recommended 
treatment for various HBV exposures.
Transmission of perinatal HBV infection can be effectively prevented if the 
HBsAg-positive mother is identified and if her infant receives appropriate immuno­
prophylaxis. Hepatitis B vaccination and one dose of HBIG, administered within 24 
hours after birth, are 85%-95% effective in preventing both HBV infection and the 
chronic carrier state (4,5,8). Hepatitis B vaccine administered alone in either a 
three-dose or four-dose schedule (Table 1), beginning within 24 hours after birth, is
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70%-95% effective in preventing perinatal HBV infections (8,47). The infants of 
women admitted for delivery who have not had prenatal HBsAg testing pose 
problems in clinical management. Initiating hepatitis B vaccination at birth for infants 
born to these women will provide adequate postexposure prophylaxis if the mothers 
are indeed HBsAg positive. The few infections not prevented by either of these 
treatment regimens were most likely acquired in utero or may be due to very high 
levels of maternal HBV-DNA (49).
Serologic testing of infants who receive immunoprophylaxis to prevent perinatal 
infection should be considered as an aid in the long-term medical management of the 
few infants who become HBV carriers. Testing for anti-HBs and HBsAg at 9-15 months 
of age will determine the success of the therapy and, in the case of failure, will identify 
HBV carriers or infants who may require revaccination.
Recommendations for postexposure prophylaxis in circumstances other than the 
perinatal period (Table 2) have been addressed in a previous statement and are 
reprinted as Appendix A to this document.
Vaccine Efficacy and Booster Doses
Clinical trials of the hepatitis B vaccines licensed in the United States have shown 
that they are 80%-95% effective in preventing HBV infection and clinical hepatitis 
among susceptible children and adults (5,33,41,50). If a protective antibody response 
develops after vaccination, vaccine recipients are virtually 100% protected against 
clinical illness.
The duration of vaccine-induced immunity has been evaluated in long-term 
follow-up studies of both adults and children (48,51). Only the plasma-derived 
hepatitis B vaccine has been evaluated because it has had the longest clinical use; 
however, on the basis of comparable immunogenicity and short-term efficacy, similar
TABLE 2. Guide to postexposure immunoprophylaxis for exposure to hepatitis B 
virus
Type of exposure Immunoprophylaxis Reference
Perinatal Vaccination + HBIG* p. 11-12
Sexual-acute infection HBIG ± Vaccination Appendix
Sexual-chronic carrier Vaccination p. 12, 15
Household contact- 






case, known exposure HBIG ± vaccination Appendix
Infant (<12 months)- 





permucosal Vaccination ± HBIG Appendix
*HBIG = Hepatitis B immune globulin.
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results would be expected with recombinant vaccines. The magnitude of the antibody 
response induced by the primary vaccination series is predictive of antibody persis­
tence, and a logarithmic decline of antibody levels occurs over time. Among young 
adults (homosexual men and Alaskan Eskimos) who initially responded to a three- 
dose vaccine series, loss of detectable antibody has ranged from 13% to 60% after 9 
years of follow-up. For children vaccinated after the first year of life, the rate of 
antibody decline has been lower than for adults (57). The peak antibody titers for 
infants are lower than those for children immunized after 12 months of age, but the 
rate of antibody decline is comparable with that observed for adults in the same 
population.
Long-term studies of healthy adults and children indicate that immunologic 
memory remains intact for at least 9 years and confers protection against chronic HBV 
infection, even though anti-HBs levels may become low or decline below detectable 
levels (45,57,52). In these studies, the HBV infections were detected by the presence 
of anti-HBc. No episodes of clinical hepatitis were reported and HBsAg was not 
detected, although brief episodes of viremia may not have been detected because of 
infrequent testing. The mild, inapparent infections among persons who have been 
previously vaccinated should not produce the sequelae associated with chronic HBV 
infection and should provide lasting immunity. In general, follow-up studies of 
children vaccinated at birth to prevent perinatal HBV infection have shown that a 
continued high level of protection from chronic HBV infections persists at least 5 
years (52,53).
For children and adults whose immune status is normal, booster doses of vaccine 
are not recommended, nor is serologic testing to assess antibody levels necessary. 
The possible need for booster doses will be assessed as additional information 
becomes available. For hemodialysis patients, vaccine-induced protection may be 
less complete and may persist only as long as antibody levels are ^10 mlU/mL. For 
these patients, the need for booster doses should be assessed by annual antibody 
testing, and a booster dose should be administered when antibody levels decline to 
<10 mlU/mL.
Vaccine Side Effects and Adverse Reactions
Hepatitis B vaccines have been shown to be safe when administered to both adults 
and children. Over 4 million adults have been vaccinated in the United States, and at 
least that many children have received hepatitis B vaccine worldwide.
Vaccine-associated side effects
Pain at the injection site (3%-29%) and a temperature greater than 37.7 C (1%-6%) 
have been among the most frequently reported side effects among adults and 
children receiving vaccine (5,37-33,50). In placebo-controlled studies, these side 
effects were reported no more frequently among vaccinees than among persons 
receiving a placebo (33,50). Among children receiving both hepatitis B vaccine and 
DTP vaccine, these mild side effects have been observed no more frequently than 
among children receiving DTP vaccine alone.
Serious adverse events
In the United States, surveillance of adverse reactions has shown a possible 
association between Guillain-Barr6 syndrome (GBS) and receipt of the first dose of
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plasma-derived hepatitis B vaccine (54, CDC unpublished data). GBS was reported at 
a very low rate (0.5/100,000 vaccinees), no deaths were reported, and all reported 
cases were among adults. An estimated 2.5 million adults received one or more doses 
of recombinant hepatitis B vaccine during the period 1986-1990. Available data from 
reporting systems for adverse events do not indicate an association between receipt 
of recombinant vaccine and GBS (CDC, unpublished data).
Until recently, large-scale hepatitis B vaccination programs for infants (e.g., 
Taiwan, Alaska, and New Zealand) have primarily used plasma-derived hepatitis B 
vaccine. No association has been found between vaccination and the occurrence of 
severe adverse events, including seizures and GBS (55, B. McMahon and A. Milne, 
unpublished data). However, systematic surveillance for adverse reactions has been 
limited in these populations, and only a small number of children have received 
recombinant vaccine. Any presumed risk of adverse events possibly associated with 
hepatitis B vaccination must be balanced against the expected risk of acute and 
chronic liver disease associated with the current 5% lifetime risk of HBV infection in 
the United States. It is estimated that, for each U.S. birth cohort, 2,000-5,000 persons 
will die from HBV-related liver disease.
As hepatitis B vaccine is introduced for routine vaccination of infants, surveillance 
for vaccine-associated adverse events will continue to be an important part of the 
program in spite of the current record of safety. Any adverse event suspected to be 
associated with hepatitis B vaccination should be reported to the Vaccine Adverse 
Event Reporting System (VAERS). VAERS forms can be obtained by calling 1- 
800-822-7967.
RECOMMENDATIONS
Prevention of Perinatal Hepatitis B Virus Infection
1. All pregnant women should be routinely tested for HBsAg during an early prenatal 
visit in each pregnancy, preferably at the same time other routine prenatal 
laboratory testing is done. HBsAg testing should be repeated late in the pregnancy 
for women who are HBsAg negative but who are at high risk of HBV infection (e.g., 
injecting drug users, those with intercurrent sexually transmitted diseases) or who 
have had clinically apparent hepatitis. Tests for other HBV markers are not 
necessary for the purpose of maternal screening. However, HBsAg-positive 
women identified during screening may have HBV-related liver disease and should 
be evaluated (56 ).
2. Infants born to mothers who are HBsAg positive should receive the appropriate 
doses of hepatitis B vaccine (Table 1) and HBIG (0.5 mL) within 12 hours of birth. 
Both should be administered by intramuscular injection. Hepatitis B vaccine 
should be administered concurrently with HBIG but at a different site. Subsequent 
doses of vaccine should be administered according to the recommended schedule 
(Table 3).
3. Women admitted for delivery who have not had prenatal HBsAg testing should 
have blood drawn for testing. While test results are pending, the infant should 
receive hepatitis B vaccine within 12 hours of birth, in a dose appropriate for 
infants born to HBsAg-positive mothers (Table 1).
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a. If the mother is later found to be HBsAg positive, her infant should receive the 
additional protection of HBIG as soon as possible and within 7 days of birth, 
although the efficacy of HBIG administered after 48 hours of age is not known 
(57). If HBIG has not been administered, it is important that the infant receive 
the second dose of hepatitis B vaccine at 1 month and not later than 2 months 
of age because of the high risk of infection. The last dose should be adminis­
tered at age 6 months (Table 3).* 
b. If the mother is found to be HBsAg negative, her infant should continue to 
receive hepatitis B vaccine as part of his or her routine vaccinations (Tables 3 
and 4), in the dose appropriate for infants born to HBsAg-negative mothers 
(Table 1).
4. In populations in which screening pregnant women for HBsAg is not feasible, all 
infants should receive their first dose of hepatitis B vaccine within 12 hours of birth, 
their second dose at 1-2 months of age, and their third dose at 6 months of age as 
a part of their childhood vaccinations and well-child care (Table 3).
5. Household contacts and sex partners of HBsAg-positive women identified through 
prenatal screening should be vaccinated. The decision to do prevaccination testing 
of these contacts to determine susceptibility to HBV infection should be made 
according to the guidelines in the section "Prevaccination testing for
*lf a four-dose schedule is used (Tables 1 and 3), the second and third doses should be 
administered at 1 and 2 months of age, respectively, and the fourth dose at 12-18 months of age.
TABLE 3. Recommended schedule of hepatitis B immunoprophylaxis to prevent 
perinatal transmission of hepatitis B virus infection












*HBsAg = Hepatitis B surface antigen.
+See Table 1 for appropriate vaccine dose.
5Hepatitis B immune globulin (HBIG)-0.5 mL administered intramuscularly at a site different 
from that used for vaccine.
f lf four-dose schedule (Engerix-B) is used, the third dose is administered at 2 months of age and 
the fourth dose at 12-18 months.
**First dose = dose for infant of HBsAg-positive mother (see Table 1). If mother is found to be 
HBsAg positive, continue that dose; if mother is found to be HBsAg negative, use appropriate 
dose from Table 1.
t+lnfants of women who are HBsAg negative can be vaccinated at 2 months of age.
Age of infant
Birth (within 12 hours)
If mother is found to be HBsAg 
positive, administer dose to 
infant as soon as possible, not 




Birth (within 12 hours) 
Birth (within 12 hours) 
1 month 
6 months1
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susceptibility/' Hepatitis B vaccine should be administered at the age-appropriate 
dose (Table 1) to those determined to be susceptible or judged likely to be 
susceptible to infection.
Universal Vaccination of Infants Born to HBsAg-Negative Mothers
1. Hepatitis B vaccination is recommended for all infants, regardless of the HBsAg 
status of the mother. Hepatitis B vaccine should be incorporated into vaccination 
schedules for children. The first dose can be administered during the newborn 
period, preferably before the infant is discharged from the hospital, but no later 
than when the infant is 2 months of age (Table 4). Because the highest titers of 
anti-HBs are achieved when the last two doses of vaccine are spaced at least 4 
months apart, schedules that achieve this spacing may be preferable (Table 4). 
However, schedules with 2-month intervals between doses, which conform to 
schedules for other childhood vaccines, have been shown to produce a good 
antibody response (Table 4) and may be appropriate in populations in which it is 
difficult to ensure that infants will be brought back for all their vaccinations. The 
development of combination vaccines containing HBsAg may lead to other 
schedules that will allow optimal use of combined antigens.
2. Special efforts should be made to ensure that high levels of hepatitis B vaccination 
are achieved in populations in which HBV infection occurs at high rates among 
children (Alaskan Natives, Pacific Islanders, and infants of immigrants from 
countries in which HBV is endemic).
TABLE 4. Recommended schedules of hepatitis B vaccination for infants born to 
HBsAg*-negative mothers
Hepatitis B vaccine Age of infant
Option 1
Dose 1 Birth-before hospital discharge
Dose 2 1-2 months*
Dose 3 6-18 monthsf
Option 2
Dose 1 1-2 months*
Dose 2 4 monthst
Dose 3 6-18 months*
*HBsAg = Hepatitis B surface antigen.
fHepatitis B vaccine can be administered simultaneously with diphtheria-tetanus-pertussis, 
Haemophilus influenzae type b conjugate, measles-mumps-rubella, and oral polio vaccines at 
the same visit.
Vaccination of Adolescents
All adolescents at high risk of infection because they are injecting drug users or 
have multiple sex partners (more than one partner/6 months) should receive hepatitis 
B vaccine. Widespread use of hepatitis B vaccine is encouraged. Because risk factors 
are often not identified directly among adolescents, universal hepatitis B vaccination 
of teenagers should be implemented in communities where injecting drug use, 
pregnancy among teenagers, and/or sexually transmitted diseases are common.
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Adolescents can be vaccinated in school-based clinics, community health centers, 
family planning clinics, clinics for the treatment of sexually transmitted diseases, and 
special adolescent clinics.
The 0-, 1-, and 6-month schedule is preferred for vaccinating adolescents with the 
age-appropriate dose of vaccine (Table 1). However, the choice of vaccination 
schedule should take into account the feasibility of delivering three doses of vaccine 
over a given period of time. The use of alternate schedules (e.g., 0, 2, and 4 months) 
may be advisable to achieve complete vaccination.
Vaccination of Selected High-Risk Groups
Efforts to vaccinate persons at high risk of HBV infection should follow the vaccine 
doses shown in Table 1. High-risk groups for whom vaccination is recommended 
include:
1. Persons with occupational risk. HBV infection is an occupational hazard for 
health-care workers and for public-safety workers who have exposure to blood 
in the workplace (24,58). The risk of acquiring HBV infections from occupa­
tional exposures depends on the frequency of percutaneous and permucosal 
exposure to blood or blood-contaminated body fluids. Any health-care or 
public-safety worker may be at risk for HBV exposure, depending on the tasks 
he or she performs. Workers who perform tasks involving contact with blood 
or blood-contaminated body fluid should be vaccinated (24,58,59). For public- 
safety workers whose exposure to blood is infrequent, timely postexposure 
prophylaxis should be considered rather than routine preexposure vaccina­
tion.
For persons in health-care fields, vaccination should be completed during 
training in schools of medicine, dentistry, nursing, laboratory technology, and 
other allied health professions, before trainees have their first contact with 
blood.
2. Clients and staff o f institutions for the deve/opmenta/iy disabled. Susceptible 
clients in institutions for the developmentally disabled, as well as staff who 
work closely with clients, should be vaccinated. Susceptible clients and staff 
who live or work in smaller residential settings with known HBV carriers 
should also receive hepatitis B vaccine. Clients discharged from residential 
institutions into community programs should be screened for HBsAg so that 
appropriate measures can be taken to prevent HBV transmission. These 
measures should include both environmental controls and appropriate use of 
vaccine.
Staff of nonresidential day-care programs for the developmentally disabled 
(e.g., schools, sheltered workshops) attended by known HBV carriers have a 
risk of infection comparable with that of health-care workers and therefore 
should be vaccinated (60). The risk of infection for other clients appears to be 
lower than the risk for staff. Vaccination of clients in day care programs may be 
considered. Vaccination of classroom contacts is strongly encouraged if a 
classmate who is an HBV carrier behaves aggressively or has special medical 
problems (e.g., exudative dermatitis, open skin lesions) that increase the risk of 
exposure to his or her blood or serous secretions.
3. Hemodialysis patients. Hepatitis B vaccination is recommended for suscepti­
ble hemodialysis patients. Vaccinating patients early in the course of their
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renal disease is encouraged because patients with uremia who are vaccinated 
before they require dialysis are more likely to respond to the vaccine (61). 
Although their seroconversion rates and anti-HBs titers are lower than those of 
healthy persons, patients who respond to vaccination will be protected from 
infection, and the need for frequent serologic testing will be reduced (62).
4. Recipients of certain blood products. Patients who receive clotting-factor 
concentrates have an increased risk of HBV infection and should be vaccinated 
as soon as their specific clotting disorder is identified. Prevaccination testing is 
recommended for patients who have already received multiple infusions of 
these products.
5. Household contacts and sex partners of HBV carriers. All household and 
sexual contacts of persons identified as HBsAg positive should be vaccinated. 
The decision to do prevaccination testing to determine susceptibility to HBV 
infection should be made according to the guidelines described earlier in the 
section "Prevaccination testing for susceptibility." Hepatitis B vaccine should 
be administered at the age-appropriate dose (Table 1) to those determined to 
be susceptible or judged likely to be susceptible to infection.
6. Adoptees from countries where HBV infection is endemic. Adopted or 
fostered orphans or unaccompanied minors from countries where HBV infec­
tion is endemic should be screened for HBsAg (3). If the children are HBsAg 
positive, other family members should be vaccinated (63).
7. International travelers. Vaccination should be considered for persons who 
plan to spend more than 6 months in areas with high rates of HBV infection 
and who will have close contact with the local population. Short-term travelers 
who are likely to have contact with blood (e.g., in a medical setting) or sexual 
contact with residents of areas with high or intermediate levels of endemic 
disease should be vaccinated. Vaccination should begin at least 6 months 
before travel to allow for completion of the full vaccine series, although a 
partial series will offer some protection. The alternate four-dose schedule (see 
Table 1) should provide protection if the first three doses can be delivered 
before departure.
8. Injecting drug users. All injecting drug users who are susceptible to HBV 
should be vaccinated as soon as their drug use begins. Because of the high 
rate of HBV infection in this population, prevaccination screening should be 
considered as outlined in the section "Prevaccination testing for susceptibil­
ity." Injecting drug users known to have HIV infection should be tested for 
anti-HBs response after completion of the vaccine series. Those who do not 
respond to vaccination should be counseled accordingly.
9. Sexually active homosexual and bisexual men. Susceptible sexually active 
homosexual and bisexual men should be vaccinated. Because of the high rate 
of HBV infection in this population, prevaccination screening should be 
considered as described in the section "Prevaccination testing for susceptibil­
ity." Men known to have HIV infection should be tested for anti-HBs response 
after completion of the vaccine series. Those who do not respond to vaccina­
tion should be counseled accordingly.
10. Sexually active heterosexual men and women. Vaccination is recommended 
for men and women who are diagnosed as having recently acquired other 
sexually transmitted diseases, for prostitutes, and for persons who have a
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history of sexual activity with more than one partner in the previous 6 months 
(2). Most patients seen in clinics for sexually transmitted diseases should be 
considered candidates for vaccination.
11. Inmates of long-term correctional facilities. Prison officials should consider 
undertaking screening and vaccination programs directed at inmates with 
histories of high-risk behaviors.
EVOLVING ISSUES IN HEPATITIS B IMMUNIZATION  
PROGRAMS
Hepatitis B vaccine has now been used extensively throughout the world and is 
currently being incorporated into the Expanded Programme on Immunization of the 
World Health Organization (16). New information, vaccines, and technology will have 
implications for this effort, and adjustments and changes are expected to occur over 
the years. Some of the issues that can be expected to be addressed in clinical and 
operational studies include the following:
1. In most developing countries with hepatitis B immunization programs, the first 
dose of vaccine is administered to all infants soon after birth to prevent 
perinatal infections; pregnant women are not screened for HBsAg; and HBIG is 
not used (8,16,45). The feasibility and effectiveness of incorporating this 
approach into the hepatitis B prevention strategy for the United States must be 
evaluated.
2. Booster doses of hepatitis B vaccine have not been recommended because of 
the persistence of protective efficacy 9 years after vaccination (48,51). The 
duration of protective efficacy for adolescents who were vaccinated during 
infancy or childhood must be evaluated; the results will determine future 
recommendations concerning booster doses.
3. Flexible dosage schedules are required to effectively integrate hepatitis B 
vaccine into current and future immunization programs for infants. Schedules 
may change as optimum dosage and timing are studied and new information 
becomes available.
4. Multiple-antigen vaccines that incorporate HBsAg as one component are 
currently being evaluated. The routine use of these vaccines may alter child­
hood vaccination schedules or may result in the administration of additional 
doses of certain antigens. However, these vaccines should greatly facilitate 
vaccine delivery and minimize the number of injections.
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APPENDIX A
Postexposure Prophylaxis for Hepatitis B
Adapted from: CDC. Protection against viral hepatitis: recommendations of the 
Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(No.RR-2):17-
22.
INTRODUCTION
Prophylactic treatment to prevent infection after exposure to HBV should be 
considered in the following situations: perinatal exposure of an infant born to an 
HBsAg-positive mother, inadvertent percutaneous or permucosal exposure to 
HBsAg-positive blood, sexual exposure to an HBsAg-positive person, and household 
exposure of an infant <12 months of age to a primary care-giver who has acute 
hepatitis B.
Various studies have established the relative efficacies of HBIG and/or hepatitis B 
vaccine in different exposure situations. For an infant with perinatal exposure to an 
HBsAg-positive and HBeAg-positive mother, a regimen combining one dose of HBIG 
at birth with the hepatitis B vaccine series started soon after birth is 85%-95% effective 
in preventing development of the HBV carrier state (A1-A3). Regimens involving 
either multiple doses of HBIG alone or the vaccine series alone have 70%-90% efficacy 
(A4,A5).
For inadvertent perrcutaneous exposure, only regimens including HBIG and/or 
immune globulin (IG) have been studied. A regimen of two doses of HBIG, one given 
after exposure and one a month later, is about 75% effective in preventing hepatitis 
B in this setting (A6,A7). For sexual exposure to a person with acute hepatitis B, a 
single dose of HBIG is 75% effective if administered within 2 weeks of last sexual 
exposure (A8). The efficacy of IG for postexposure prophylaxis is uncertain; IG no 
longer has a role in postexposure prophylaxis of hepatitis B because of the availability 
of HBIG and the wider use of hepatitis B vaccine.
Recommendations on postexposure prophylaxis are based on available efficacy 
data and on the likelihood of future HBV exposure for the person requiring treatment. 
In all exposures, a regimen combining HBIG with hepatitis B vaccine will provide both 
short- and long-term protection, will be less costly than the two-dose HBIG treatment 
alone, and is the treatment of choice.
Acute Exposure to Blood that Contains (or Might Contain) HBsAg
For inadvertent percutaneous (needlestick, laceration, or bite) or permucosal 
(ocular or mucous-membrane) exposure to blood, the decision to provide prophylaxis 
must include consideration of several factors: a) whether the source of the blood is 
available; b) the HBsAg status of the source; and c) the hepatitis B vaccination and 
vaccine-response status of the exposed person. Such exposures usually affect 
persons for whom hepatitis B vaccine is recommended. For any exposure of a person 
not previously vaccinated, hepatitis B vaccination is recommended.
After any such exposure, a blood sample should be obtained from the person who 
was the source of the exposure and should be tested for HBsAg. The hepatitis B
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vaccination status and anti-HBs response status (if known) of the exposed person 
should be reviewed. The outline below and Table A1 summarize prophylaxis for 
percutaneous or permucosal exposure to blood according to the HBsAg status of the 
source of exposure and the vaccination status and vaccine response of the exposed 
person. For greatest effectiveness, passive prophylaxis with HBIG, when indicated, 
should be administered as soon as possible after exposure since its value beyond 7 
days after exposure is unclear.
1. Source of exposure known and HBsAg positive
a. Exposed person has not been vaccinated or has not completed vaccination. 
Hepatitis B vaccination should be initiated. A single dose of HBIG (0.06 mL/kg) 
should be administered as soon as possible after exposure and within 24 hours, 
if possible. The first dose of hepatitis B vaccine should be administered 
intramuscularly at a separate site (deltoid for adults) and can be administered 
simultaneously with HBIG or within 7 days of exposure; subsequent doses 
should be administered as recommended for the specific vaccine. If the exposed 
person has begun but has not completed vaccination, one dose of HBIG should 
be administered immediately and vaccination should be completed as sched­
uled.
b. Exposed person has already been vaccinated against hepatitis B, and anti-HBs 
response status is known.
TABLE A1. Recommendations for hepatitis B prophylaxis following percutaneous 
exposure
Treatment when source is found to be
Exposed person HBsAg positive HBsAg negative
Unknown or 
not tested
Un vaccinated Administer HBIG x 1* and 
initiate hepatitis B vaccine*
Initiate hepatitis B 
vaccinef
Initiate hepatitis B 
vaccine*
Previously vaccinated
Known responder Test exposed person 
for anti-HBs
1. If adequate, 
no treatment
2. If inadequate, 
hepatitis B
vaccine booster dose
No treatment No treatment
Known non­
responder
HBIG x 2 or
HBIG x 1, plus 1 dose
of hepatitis B vaccine
No treatment If known high-risk 
source, may treat as 




Test exposed person 
for anti-HBs
1. If inadequate
HBIG x 1, plus hepatitis 
B vaccine booster dose
2. If adequate, no treatment
No treatment Test exposed person 
for anti-HBs5
1. If inadequate, 
hepatitis B vaccine 
booster dose
2. If adequate, 
no treatment
♦Hepatitis B immune globulin (HBIG) dose 0.06 mL/kg intramuscularly, 
hepatitis B vaccine dose-see Table 1.
5Adequate anti-HBs is ^10 milli-international units.
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(1) If the exposed person is known to have had adequate response in the past, 
the anti-HBs level should be tested unless an adequate level has been 
demonstrated within the last 24 months. Although current data show that 
vaccine-induced protection does not decrease as antibody level wanes, 
most experts consider the following approach to be prudent:
(a) If the anti-HBs level is adequate, no treatment is necessary.
(b) If the anti-HBs level is inadequate,* a booster dose of hepatitis B vaccine 
should be administered.
(2) If the exposed person is known not to have responded to the primary 
vaccine series, he or she should receive either a single dose of HBIG and a 
dose of hepatitis B vaccine as soon as possible after exposure, or two doses 
of HBIG (0.06 mL/kg), one as soon as possible after exposure and the second 
1 month later. The latter treatment is preferred for those who have not 
responded to at least four doses of vaccine.
c. Exposed person has already been vaccinated against hepatitis B, and the 
anti-HBs response is unknown. The exposed person should be tested for 
anti-HBs.
(1) If the exposed person has adequate antibody, no additional treatment is 
necessary.
(2) If the exposed person has inadequate antibody on testing, one dose of HBIG 
(0.06 mL/kg) should be administered immediately and a standard booster 
dose of vaccine administered at a different site.
2. Source of exposure known and HBsAg-negative
a. Exposed person has not been vaccinated or has not completed vaccination. If 
unvaccinated, the exposed person should be administered the first dose of 
hepatitis B vaccine within 7 days of exposure, and vaccination should be 
completed as recommended. If the exposed person has not completed vacci­
nation, vaccination series should be completed as scheduled.
b. Exposed person has already been vaccinated against hepatitis B. No treatment 
is necessary.
3. Source of exposure unknown or not available for testing.
a. Exposed person has not been vaccinated or has not completed vaccination. If 
unvaccinated, the exposed person should be administered the first dose of 
hepatitis B vaccine within 7 days of exposure and vaccination should be 
completed as recommended. If the exposed person has not completed vacci­
nation, vaccination should be completed as scheduled.
b. Exposed person has already been vaccinated against hepatitis B, and anti-HBs 
response status is known.
(1) If the exposed person is known to have had adequate response in the past, 
no treatment is necessary.
(2) If the exposed person is known not to have responded to the vaccine, 
prophylaxis as described earlier in section 1.b.(2) under "Source of expo­
sure known and HBsAg-positive" may be considered if the source of the 
exposure is known to be at high risk of HBV infection.
c. Exposed person has already been vaccinated against hepatitis B, and the 
anti-HBs response is unknown. The exposed person should be tested for 
anti-HBs.
*An adequate antibody level is ^10 mlU/mL.
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(1) If the exposed person has adequate anti-HBs, no treatment is necessary.
(2) If the exposed person has inadequate anti-HBs, a standard booster dose of 
vaccine should be administered.
Sex Partners of Persons with Acute Hepatitis B Virus Infection
Sex partners of HBsAg-positive persons are at increased risk of acquiring HBV 
infection, and HBIG has been shown to be 75% effective in preventing such infections 
(A8). Because data are limited, the period after sexual exposure during which HBIG 
is effective is unknown, but extrapolation from other settings makes it unlikely that 
this period would exceed 14 days. Before treatment, testing sex partners for 
susceptibility is recommended if it does not delay treatment beyond 14 days after last 
exposure. Testing for anti-HBc is the most efficient prescreening procedure to use in 
this population.
All susceptible persons whose sex partners have acute hepatitis B infection should 
receive a single dose of HBIG (0.06 mL/kg) and should begin the hepatitis B vaccine 
series if prophylaxis can be started within 14 days of the last sexual contact or if 
sexual contact with the infected person will continue. Administering the vaccine with 
HBIG may improve the efficacy of postexposure treatment. The vaccine has the added 
advantage of conferring long-lasting protection.
An alternate treatment for persons who are not from a high-risk group for whom 
vaccine is routinely recommended and whose regular sex partners have acute HBV 
infection is to administer one dose of HBIG (without vaccine) and retest the sex 
partner for HBsAg 3 months later. No further treatment is necessary if the sex partner 
becomes HBsAg negative. If the sex partner remains HBsAg positive, a second dose 
of HBIG should be given and the hepatitis B vaccine series started.
Household Contacts of Persons with Acute Hepatitis B Virus Infection
Since infants have close contact with primary care-givers and they have a higher 
risk of becoming HBV carriers after acute HBV infection, prophylaxis of an infant less 
than 12 months of age with HBIG (0.5 mL) and hepatitis B vaccine is indicated if the 
mother or primary care-giver has acute HBV infection. Prophylaxis for other house­
hold contacts of persons with acute HBV infection is not indicated unless they have 
had identifiable blood exposure to the index patient, such as by sharing toothbrushes 
or razors. Such exposures should be treated like sexual exposures. If the index patient 
becomes an HBV carrier, all household contacts should receive hepatitis B vaccine.
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